Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

References

• Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 2005;64(Suppl II):ii14-17
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53:573-7
   PubMed Web of Science ®Google Scholar
• Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009;61:1373-8
   PubMed Web of Science ®Google Scholar
• Feuchtenberger M, Kleinert S, Tony H-P, et al. Psoriatic arthritis: therapeutic principles. Clin Dermatol 2008;26:460-3
   PubMed Web of Science ®Google Scholar
• Husted JA, Tom BDM, Farewell VT, et al. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis. Arthritis Rheum 2007;56:840-9
   PubMed Web of Science ®Google Scholar
• Borman P, Toy GG, Babaoglu S, et al. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheum 2007;26:330-4
   PubMed Web of Science ®Google Scholar
• Mease PJ. Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum 2008;38:320-35
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mcinnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9
   PubMed Web of Science ®Google Scholar
• Mease PJ, Wooley JM, Singh A, et al. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 2010;37:1221-7
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006;65:471-7
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010;162:137-46
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol 10.1016/j.jaad.2009.09.014
   Google Scholar
• Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15
   PubMed Web of Science ®Google Scholar
• Felson D, Anderson J, Boers M, et al. American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis. Arthritis Rheum 1995;38:727-35
   PubMed Web of Science ®Google Scholar
• Fredricksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238-44
   PubMedGoogle Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6
   PubMed Web of Science ®Google Scholar
• Lundberg L, Johannesson M, Silverdahl M, et al. Quality of Life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Reich C, et al. Quality of psoriasis care in Germany – results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 2008;6:640-5
   PubMed Web of Science ®Google Scholar
• Reich K, Sinclair R, Roberts G, et al. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin 2008;24:1237-54
   PubMed Web of Science ®Google Scholar
• Shikiar R, Bresnahan BW, Stone SP, et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003;1:53-61
   PubMedGoogle Scholar
• Hawley DJ, Wolfe F. Sensitivity to change of the health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis. Arthr Care Res 1992;5:130-6
   PubMedGoogle Scholar
• Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006;24(Suppl 43):s83-7
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93
   PubMed Web of Science ®Google Scholar
• Husted JA, Gladman DD, Long JA, et al. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995;13:439-43
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ganguly R, Wanke L, et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004;63 (Suppl 1):391
   Google Scholar
• Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6
   PubMed Web of Science ®Google Scholar
• Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthr Care Res 2001;45:151-8
   Web of Science ®Google Scholar
• Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006;8:355-63
   PubMedGoogle Scholar
• Han C, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
   PubMed Web of Science ®Google Scholar
• Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007;25:529-34
   PubMed Web of Science ®Google Scholar
• Both H, Essink-Bot ML, Busschbach J, et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007;127:2726-39
   PubMed Web of Science ®Google Scholar
• Le Cleach L, Chassany O, Levy A, et al. Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2008;216:46-55
   PubMed Web of Science ®Google Scholar
• Gladman DD, Helliwell P, Mease PJ, et al. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT-2 trial. Ann Rheum Dis 2005;64:1150-7
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007;66:163-8
   PubMed Web of Science ®Google Scholar